In this regards, since IL-27 has much less toxicities compared with IL-12 [41, 46], probably due to much lower ability of IL-27 to produce IFN-γ by NK cells, IL-27 may be an attractive candidate as an antitumor agent applicable to cancer immunotherapy. The gene discussed is IFNG; the disease is cancer.